Oncology and Hematology - Global Oncology Academy

513-528 of 790

Management of HR+, HER2- High-Risk EBC
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD; Erica L. Mayer, MD, MPH
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Sara Lonardi, MD; Aparna R. Parikh, MD
1.25 credits 10 episodes
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 credits 10 episodes
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Project Oncology®
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Ben Park, MD, PhD
- Ben Park, MD, PhD
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits

33/11